Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01503684

Enrollment

300

Registered

2012-01-04

Start date

2011-08-31

Completion date

Unknown

Last updated

2012-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis

Brief summary

In this proposal, the investigators wish to investigate, identify and validate potential biomarkers in collected exhaled breath condensates (EBC) from patients with sepsis.

Detailed description

In this proposed project, we will focus on the identification of potential biomarkers in EBC with ability to predict development of multi-organ failure. Currently, no tools could be used to evaluate the effect of mitochondrial dysfunction in sepsis. All the human studies discussing mitochondrial dysfunction in sepsis use tissue biopsies as study materials. Repeated tissue biopsy is invasive and not applicable. EBC could be collected non-invasively and conveniently. A study has demonstrated the use of metabolomic technologies in mitochondrial diseases. We believe that the metabolomic biomarkers of EBC could be used to demonstrate mitochondrial dysfunction in lungs and respiratory tracts of septic patients. Such metabolomic biomarkers may also reflect similar on-going mitochondrial dysfunction in other organ systems, and could potentially become a novel diagnostic tool and a therapeutic target in future sepsis therapy.

Interventions

OTHERDetermined by intended physician

We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* above 20 years old * admitted to ICU with the diagnosis of sepsis and treated with mechanical ventilation via an endotracheal tube

Exclusion criteria

* pregnant * active malignancy * in an immunosuppressed status such as HIV disease, neutropenia, being treated with immunosuppressive agents * expected to have an unavoidable very short life expectancy after admission, i.e., \< 3 days

Design outcomes

Primary

Measure	Time frame	Description
Development and severity of sepsis	28 days	To record APACHE II, SOFA, and MODS, etc.

Secondary

Measure	Time frame
Mortality	28 days
Response to treatment and progression of organ failure	28 days

Countries

Taiwan

Contacts

Primary ContactJih-Shuin Jerng, MD,PhD

jsjerng@ntu.edu.tw886-2-23562905

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026